Cipla (LUX:CIPLA) Total Operating Expense: $1,506 Mil (TTM As of Mar. 2026)


LUX:CIPLA Cipla Ltd LUX:CIPLA
93 GF Score
Price $18.10
GF Value $19.69
! 5 Warning Signs
View Full Analysis

What is Cipla Total Operating Expense?

Cipla LUX:CIPLA 93 Total Operating Expense is $1,506 Mil as of Mar. 2026. GuruFocus rates LUX:CIPLA with a GF Score™ of 93/100 and a GF Value™ of $19.69. The stock has 5 warning signs investors should review.

Cipla's Total Operating Expense for the three months ended in Mar. 2026 was $388 Mil. Cipla's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $1,506 Mil.

Cipla Total Operating Expense Related Terms

Cipla Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Cipla's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipla Total Operating Expense Chart

Cipla Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,158.06 1,154.14 1,263.00 1,298.92 1,337.46

Cipla Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 367.52 365.75 379.53 372.54 388.02
LUX:CIPLA
93GF Score
Cipla Ltd LUX:CIPLA
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cipla Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,506 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $1,506 Mil mean?
Cipla (LUX:CIPLA) has a Total Operating Expense of $1,506 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Cipla and its competitors.
Is Cipla's Total Operating Expense too high?
Cipla's current Total Operating Expense is $1,506 Mil. Overall, Cipla has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's Total Operating Expense compare to ZTS and UTHR?
Cipla's Total Operating Expense of $1,506 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Cipla and its competitors. Cipla's current Total Operating Expense is $1,506 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (LUX:CIPLA) has a current Total Operating Expense of $1,506 Mil. The stock's GF Value™ is $19.69, compared to a current price of $18.10 — trading 8.1% below its estimated fair value. The current Total Operating Expense is $1,506 Mil. Cipla's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Cipla (LUX:CIPLA), the current Total Operating Expense is $1,506 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipla (LUX:CIPLA) Overvalued in 2026?

Based on GuruFocus' analysis, Cipla stock appears to be undervalued. The current stock price of $18.10 is trading 8.1% below its estimated GF Value™ of $19.69.

Key valuation signals for LUX:CIPLA:

  • Total Operating Expense: $1,506 Mil
  • GF Value™: $19.69 vs. price of $18.10 (8.1% below fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the LUX:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cipla Business Description

Other Exchanges CIPLA:India500087:India
Address Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
93GF Score

Get the complete analysis for LUX:CIPLA

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.10
Price
$19.69
GF Value